Drug Information
Drug (ID: DG01868) and It's Reported Resistant Information
Type(s) of Resistant Mechanism of This Drug
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
|
||||
Key Molecule: GTPase Hras (HRAS) | [1] | |||
Molecule Alteration | Missense mutation | p.Q61L (c.182A>T) |
||
Sensitive Disease | Bladder cancer [ICD-11: 2C94.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Ras signaling pathway | Inhibition | hsa04014 | |
In Vitro Model | A375 cells | Skin | Homo sapiens (Human) | CVCL_0132 |
HEK293T cells | Kidney | Homo sapiens (Human) | CVCL_0063 | |
T24 cells | Bladder | Homo sapiens (Human) | CVCL_0554 | |
HEK293 cells | Kidney | Homo sapiens (Human) | CVCL_0045 | |
NIH3T3 cells | Embryo | Homo sapiens (Human) | N.A. | |
COS cells | N.A. | . | N.A. | |
Experiment for Drug Resistance |
Promega assay | |||
Mechanism Description | NS1, that bound with high affinity to both GTP- and GDP-bound states of H- and K-RAS but not N-RAS. NS1 potently inhibited growth factor signaling and oncogenic H- and K-RAS-mediated signaling and transformation but did not block oncogenic N-RAS, BRAF or MEK1. NS1 bound the alpha4-beta6-alpha5 region of RAS disrupting RAS dimerization/nanoclustering, which in turn blocked CRAF:BRAF heterodimerization and activation. These results establish the importance of the alpha4-beta6-alpha5 interface in RAS-mediated signaling and define a previously unrecognized site in RAS for inhibiting RAS function. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.